2024 Insurance Coverage and Processing Packaging 
PharmaTech
JUNE 10, 2025
It provides evidence-based recommendations on the use of vaccines for children and adults, informs decisions about insurance coverage, and helps determine eligibility for publicly funded programs such as Vaccines for Children (VFC). ACIP plays a foundational role in shaping immunization policy in the US. BIO President and CEO John F.
Pharmaceutical Technology
JUNE 6, 2025
The approval process for cell and gene therapy candidates is tricky, however, given their high-cost and oft-debated benefit-risk ratio. RFK Jr did not question their importance, and acknowledged panellists’ calls for faster regulatory processes. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
MARCH 16, 2025
What are the top 3 trends that defined pharma manufacturing in India and globally in 2024? In 2024, the pharmaceutical manufacturing landscape underwent transformative changes, driven by technological innovations, regulatory adaptations, and evolving global demands. Regulatory bodies in the U.S. and Europe.
Putting Patients First Blog
FEBRUARY 1, 2024
Health Care Riders February 1, 2024 By: Allen Pinn, Coordinator, Policy In January, the Senate and House reached an agreement to fund the government through the first week of March. We reiterated these priorities to start the year in January 2024. The House passed H.R. 5378 More Transparency, Lower Costs Act in December 2023.
Pharmaceutical Technology
JUNE 12, 2025
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. In 2023, SpliceBio signed a licensing agreement with Spark Therapeutics, allowing the latter to use its protein splicing platform and develop a gene therapy for an undisclosed inherited renal disease.
European Pharmaceutical Review
MARCH 28, 2024
FDA is expected to provide initial feedback on the data submitted by July 2024, with further data to be collected and analysed over the next two years. How does the qualification package support more meaningful endpoints and rare disease research as a result?
Putting Patients First Blog
MARCH 18, 2024
The NHC supports the development and use of processes and tools that enhance beneficiary experience, making interactions with the MPPP smoother and more intuitive for all beneficiaries. Similarly, updating the Explanation of Benefits to include visual aids and examples will clarify MPPP’s impact on cost-sharing and coverage.
Expert insights. Personalized for you.
85 
Let's personalize your content